Tauriga Sciences, Inc. announced that it has initiated a clinical trial to examine the effects of Cannabidiol (“CBD”) doses on pregnant women with the diagnosis of: Hyperemesis Gravidarum (“Morning Sickness”). More specifically, this clinical trial has been planned as a prospective, double-blind, placebo-controlled study, to examine the: Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum.